Dr. Ken Wong is Program Director for the Healthcare Decision Analysis and Biopharmaceutical Marketing graduate degree programs. He is an Associate Professor of Pharmaceutical and Health Economics at the USC School of Pharmacy.
During his professional career, he served as Director of Health Economics and Outcomes Research and Director of Managed Healthcare at Novartis Pharmaceuticals and Director of Health Services Research at Bristol Myers Squibb. Prior to the pharmaceutical industry he held pharmacy leadership positions at Cigna, Caremark, HealthNet and UniHealth. He served as an Accreditation Surveyor for the Joint Commission where he surveyed and advised healthcare systems on pharmaceutical and quality of care standards.
Dr. Wong was previously an Associate Professor at the Keck Graduate Institute, School of Pharmacy and an Adjunct Professor at the Keck Graduate Institute, Henry E. Riggs School of Applied Life Sciences.
He graduated from the University of Southern California with a Doctorate in Pharmacy and received his Masters in Public Health from the University of Massachusetts at Amherst.
Dr. Wong's research interests include innovations in drug pricing and reimbursement and the impact of health systems and care processes on patient outcomes in chronic disease care management.
Areas of Expertise (5)
Innovative Care Delivery Models
Health Economics & Outcomes Research
Market Access & Reimbursement
Innovative Pricing Models
University of Southern California: Pharm.D.
University of Massachusetts at Amherst: M.P.H.
- Novartis Pharmaceuticals
- Keck Graduate Institute
- Joint Commission
- Bristol Myers Squibb
Selected Articles (3)
Frois C, Howe A, Jarvis J, Grice K, Wong K, Zacker C, Sasane R.
2019 The U.S. health care system's transition to a value-based reimbursement model holds important implications for medical innovation, care delivery, and value-based assessments of therapeutic interventions. This transition has been especially noteworthy in oncology, with substantial ongoing changes to payer reimbursement and the provider landscape, as well as the introduction of value frameworks to guide drug treatment decision making. The implications of these changes for provider assessments of drug value and evidence needs remain unclear.
Wong K, Boulanger L, Smalarz A, Wu N, Fraser K, Wogen J.
2013 Fragmentation within health care systems may negatively impact the quality of chronic disease patient care. We sought to evaluate the relationship between care management processes (CMP), integration of services, and blood pressure (BP) control among diabetic patients.
Thornton Snider J, Luna Y, Wong KS, Zhang J, Chen SS, Gless PJ, Goldman DP.
2012 To determine the association between inhaled corticosteroid (ICS) use and the risk of pneumonia among Medicare patients with chronic obstructive pulmonary disease (COPD).